Wide Ranks

INVA

Innoviva, Inc.

19.05

Top Statistics
Market Cap 1 B Forward PE 11.11 Revenue Growth 33.10 %
Current Ratio 1.79 Trailing PE 23.81 Earnings Growth -98.00 %
Profit Margins 18.31 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 6.57 Enterprise / Revenue 4.12 Price To Sales Trailing12 Months 3.38
Profitability
Profit Margins 18.31 % Operating Margins 48.30 %
Balance Sheet
Total Cash 260 M Total Cash Per Share 4.16 Total Debt 521 M
Total Debt To Equity 78.08 Current Ratio 1.79 Book Value Per Share 10.68
All Measures
Short Ratio 2191.00 % Message Board Id finmb_24362 Shares Short Prior Month 11 M
Return On Equity 0.0997 City Burlingame Uuid 7fee3656-d883-3b1c-8337-4a733b67dfef
Previous Close 19.14 First Trade Date Epoch Utc 1 B Book Value 10.68
Beta 0.5680 Total Debt 521 M Volume 438972
Price To Book 1.78 Last Split Date 1 B Fifty Two Week Low 13.66
Total Cash Per Share 4.16 Total Revenue 352 M Shares Short Previous Month Date 1 B
Target Median Price 19.00 Audit Risk 8 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins 48.30 % Last Dividend Value 0.2500
Target Mean Price 19.00 Net Income To Common 64 M Short Percent Of Float 0.3652
Implied Shares Outstanding 62 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 962860 Average Volume10days 962860 Total Cash 260 M
Next Fiscal Year End 1 B Revenue Per Share 5.60 Held Percent Insiders 0.0107
Ebitda Margins 62.71 % Trailing PE 23.81 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 4 Regular Market Previous Close 19.14
Target Low Price 19.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 19.56
Open 19.15 Free Cashflow 129 M State CA
Dividend Yield 0.00 % Return On Assets 0.0937 Time Zone Short Name EST
Board Risk 6 Trailing Eps 0.8000 Day Low 18.95
Address1 1350 Old Bayshore Highway Shares Outstanding 62 M Compensation Risk 6
Price Hint 2 Target High Price 19.00 Website https://www.inva.com
52 Week Change 0.3755 Average Volume 604576 Earnings Quarterly Growth -98.50 %
Forward Eps 1.47 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 157.20 % Last Split Factor 1241:1000 Regular Market Day High 19.20
Is_sp_500 False Profit Margins 18.31 % Debt To Equity 78.08
Fifty Two Week High 21.28 Day High 19.20 Shares Short 11 M
Regular Market Open 19.15 Industry Key biotechnology Earnings Growth -98.00 %
Enterprise To Revenue 4.12 Revenue Growth 33.10 % Shares Percent Shares Out 0.1853
Operating Cashflow 162 M Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 94010
Quote Type EQUITY Industry Biotechnology Ex Dividend Date 1 B
Overall Risk 5 Regular Market Day Low 18.95 Held Percent Institutions 1.19
Long Name Innoviva, Inc. Address2 Suite 400 Enterprise To Ebitda 6.57
Current Price 19.05 Financial Currency USD Current Ratio 1.79
Gross Margins 84.24 % Industry Disp Biotechnology Number Of Analyst Opinions 1
Country United States Float Shares 50 M Two Hundred Day Average 17.26
Governance Epoch Date 1 B Enterprise Value 1 B Price To Sales Trailing12 Months 3.38
Forward PE 11.11 Regular Market Volume 438972 Last Dividend Date 1 B
Ebitda 221 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.

The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.

Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.

It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.

Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.